The Asia Pacific Hemoglobinopathies Market would witness market growth of 6.1% CAGR during the forecast period (2022-2028).
With the help of penicillin prophylaxis, SCD can be detected early, which drops downs the risk of Streptococcus pneumoniae (pneumococcus) infection. Additionally, if SCD is detected early, healthcare workers can educate the family about the disease and give preventive advice to provide total care to the patient. Other hemoglobinopathies seen through newborn screening are classified as secondary targets; HbE, HbSE, and HbC disease are some examples.
Newborn screening and diagnosis may differ in different laboratory programs. While some of them detect only common variants, others might identify multiple variants. While some techniques are manual and labor-intensive, others are automated. For diagnostics methods that include applications based on DNA, some procedures require highly specialized equipment.
Some Programs also have different structures. Though some laboratories only screen, others perform both diagnostic testing and screening. Before referring the patients for diagnostic testing, in some cases, a second-tier evaluation is recommended to confirm an abnormal result. Also, different programs will have additional reporting and follow-up algorithms.
Hemoglobinopathy causes a serious burden on the health care system and the families as being a primary cause of morbidity and mortality in India. There are about 1 to 1.5 lakhs Thalassemia major patients, which is the highest in the world, and about 42 million carriers of the beta thalassemia trait. Around 10,000 to 15,000 children are born annually with thalassemia major. Many regions in India are affected by sickle cell disease, like central India, Maharashtra, and Kerala.
The China market dominated the Asia Pacific Hemoglobinopathies Market by Country in 2021; thereby, achieving a market value of $506.5 Million by 2028. The Japan market is registering a CAGR of 5.5% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 6.8% during (2022 - 2028).
Based on Type, the market is segmented into Thalassemia, Sickle Cell Disease and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacy, Hospital Pharmacy and Online Providers. Based on Therapy, the market is segmented into Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Hemoglobinopathies Market is Projected to reach USD 6 Billion by 2028, at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Sanofi S.A., Danaher Corporation, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Merck & Co., Inc., Bristol Myers Squibb Company, Alnylam Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., Biogen, Inc. and Canthera Discovery Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Thalassemia
- Sickle Cell Disease
- Others
By Distribution Channel
- Drug Stores & Retail Pharmacy
- Hospital Pharmacy
- Online Providers
By Therapy
- Monoclonal Antibody Medication
- Hydroxyurea
- ACE Inhibitors
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Sanofi S.A.
- Danaher Corporation
- Pfizer, Inc. (Global Blood Therapeutics, Inc.)
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Alnylam Pharmaceuticals, Inc.
- Emmaus Life Sciences, Inc.
- Biogen, Inc.
- Canthera Discovery Ltd.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Hemoglobinopathies Market, by Type
1.4.2 Asia Pacific Hemoglobinopathies Market, by Distribution Channel
1.4.3 Asia Pacific Hemoglobinopathies Market, by Therapy
1.4.4 Asia Pacific Hemoglobinopathies Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and Scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Hemoglobinopathies Market by Type
3.1 Asia Pacific Thalassemia Market by Country
3.2 Asia Pacific Sickle Cell Disease Market by Country
3.3 Asia Pacific Others Market by Country
Chapter 4. Asia Pacific Hemoglobinopathies Market by Distribution Channel
4.1 Asia Pacific Drug Stores & Retail Pharmacy Market by Country
4.2 Asia Pacific Hospital Pharmacy Market by Country
4.3 Asia Pacific Online Providers Market by Country
Chapter 5. Asia Pacific Hemoglobinopathies Market by Therapy
5.1 Asia Pacific Monoclonal Antibody Medication Market by Country
5.2 Asia Pacific Hydroxyurea Market by Country
5.3 Asia Pacific ACE Inhibitors Market by Country
5.4 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Hemoglobinopathies Market by Country
6.1 China Hemoglobinopathies Market
6.1.1 China Hemoglobinopathies Market by Type
6.1.2 China Hemoglobinopathies Market by Distribution Channel
6.1.3 China Hemoglobinopathies Market by Therapy
6.2 Japan Hemoglobinopathies Market
6.2.1 Japan Hemoglobinopathies Market by Type
6.2.2 Japan Hemoglobinopathies Market by Distribution Channel
6.2.3 Japan Hemoglobinopathies Market by Therapy
6.3 India Hemoglobinopathies Market
6.3.1 India Hemoglobinopathies Market by Type
6.3.2 India Hemoglobinopathies Market by Distribution Channel
6.3.3 India Hemoglobinopathies Market by Therapy
6.4 South Korea Hemoglobinopathies Market
6.4.1 South Korea Hemoglobinopathies Market by Type
6.4.2 South Korea Hemoglobinopathies Market by Distribution Channel
6.4.3 South Korea Hemoglobinopathies Market by Therapy
6.5 Singapore Hemoglobinopathies Market
6.5.1 Singapore Hemoglobinopathies Market by Type
6.5.2 Singapore Hemoglobinopathies Market by Distribution Channel
6.5.3 Singapore Hemoglobinopathies Market by Therapy
6.6 Malaysia Hemoglobinopathies Market
6.6.1 Malaysia Hemoglobinopathies Market by Type
6.6.2 Malaysia Hemoglobinopathies Market by Distribution Channel
6.6.3 Malaysia Hemoglobinopathies Market by Therapy
6.7 Rest of Asia Pacific Hemoglobinopathies Market
6.7.1 Rest of Asia Pacific Hemoglobinopathies Market by Type
6.7.2 Rest of Asia Pacific Hemoglobinopathies Market by Distribution Channel
6.7.3 Rest of Asia Pacific Hemoglobinopathies Market by Therapy
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Sanofi S.A.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Trials and Approvals:
7.3 Danaher Corporation
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 Pfizer, Inc. (Global Blood Therapeutics, Inc.)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 Merck & Co., Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expenses
7.6 Bristol Myers Squibb Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Alnylam Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expense
7.8 Emmaus Life Sciences, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.9 Biogen, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.10. Canthera Discovery Ltd.
7.10.1 Company Overview
TABLE 1 Asia Pacific Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 2 Asia Pacific Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 3 Asia Pacific Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 4 Asia Pacific Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 5 Asia Pacific Thalassemia Market by Country, 2018 - 2021, USD Million
TABLE 6 Asia Pacific Thalassemia Market by Country, 2022 - 2028, USD Million
TABLE 7 Asia Pacific Sickle Cell Disease Market by Country, 2018 - 2021, USD Million
TABLE 8 Asia Pacific Sickle Cell Disease Market by Country, 2022 - 2028, USD Million
TABLE 9 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
TABLE 10 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
TABLE 11 Asia Pacific Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 12 Asia Pacific Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 13 Asia Pacific Drug Stores & Retail Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 14 Asia Pacific Drug Stores & Retail Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 15 Asia Pacific Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 16 Asia Pacific Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 17 Asia Pacific Online Providers Market by Country, 2018 - 2021, USD Million
TABLE 18 Asia Pacific Online Providers Market by Country, 2022 - 2028, USD Million
TABLE 19 Asia Pacific Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 20 Asia Pacific Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 21 Asia Pacific Monoclonal Antibody Medication Market by Country, 2018 - 2021, USD Million
TABLE 22 Asia Pacific Monoclonal Antibody Medication Market by Country, 2022 - 2028, USD Million
TABLE 23 Asia Pacific Hydroxyurea Market by Country, 2018 - 2021, USD Million
TABLE 24 Asia Pacific Hydroxyurea Market by Country, 2022 - 2028, USD Million
TABLE 25 Asia Pacific ACE Inhibitors Market by Country, 2018 - 2021, USD Million
TABLE 26 Asia Pacific ACE Inhibitors Market by Country, 2022 - 2028, USD Million
TABLE 27 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
TABLE 28 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
TABLE 29 Asia Pacific Hemoglobinopathies Market by Country, 2018 - 2021, USD Million
TABLE 30 Asia Pacific Hemoglobinopathies Market by Country, 2022 - 2028, USD Million
TABLE 31 China Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 32 China Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 33 China Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 34 China Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 35 China Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 36 China Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 37 China Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 38 China Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 39 Japan Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 40 Japan Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 41 Japan Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 42 Japan Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 43 Japan Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 44 Japan Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 45 Japan Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 46 Japan Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 47 India Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 48 India Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 49 India Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 50 India Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 51 India Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 52 India Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 53 India Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 54 India Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 55 South Korea Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 56 South Korea Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 57 South Korea Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 58 South Korea Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 59 South Korea Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 60 South Korea Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 61 South Korea Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 62 South Korea Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 63 Singapore Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 64 Singapore Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 65 Singapore Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 66 Singapore Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 67 Singapore Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 68 Singapore Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 69 Singapore Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 70 Singapore Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 71 Malaysia Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 72 Malaysia Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 73 Malaysia Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 74 Malaysia Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 75 Malaysia Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 76 Malaysia Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 77 Malaysia Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 78 Malaysia Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 79 Rest of Asia Pacific Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 80 Rest of Asia Pacific Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 81 Rest of Asia Pacific Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 82 Rest of Asia Pacific Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 83 Rest of Asia Pacific Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 84 Rest of Asia Pacific Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 85 Rest of Asia Pacific Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 86 Rest of Asia Pacific Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 87 Key Information – Abbott Laboratories
TABLE 88 Key Information – Sanofi S.A.
TABLE 89 Key Information – Danaher Corporation
TABLE 90 Key Information – Pfizer, Inc.
TABLE 91 KEY INFORMATION - Merck & Co., Inc.
TABLE 92 Key Information – Bristol Myers Squibb Company
TABLE 93 Key Information – Alnylam Pharmaceuticals, Inc.
TABLE 94 Key Information – Emmaus Life Sciences, INC.
TABLE 95 Key Information – Biogen, Inc.
TABLE 96 Key Information – Canthera Discovery Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 Swot analysis: Abbott laboratories